Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.
| Revenue (TTM) | $500.64M |
| Gross Profit (TTM) | $373.23M |
| EBITDA | $-58.27M |
| Operating Margin | -13.40% |
| Return on Equity | -12.80% |
| Return on Assets | -5.16% |
| Revenue/Share (TTM) | $47.26 |
| Book Value | $6.82 |
| Price-to-Book | 2.09 |
| Price-to-Sales (TTM) | 0.39 |
| EV/Revenue | 1.33 |
| EV/EBITDA | -0.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -9.30% |
| Shares Outstanding | $8.81M |
| Float | $3.42M |
| % Insiders | 4.03% |
| % Institutions | 47.23% |
Volatility is currently expanding
GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2026.
GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company's ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company's insider trading policy.
GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026. Recent Business Updates Early Detection, Therapy Selection & MRD Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.
GUANGZHOU, China, April 28, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 28, 2026 it filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company's website at http://ir.brbiotech.com.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BNR and any ticker you trade — then tracks every position and per-strategy win rate.
